ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Acumen Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jul 13, 2021 7:13pm

151 Views

Post# 33540204

RE:RE:Acumen Pharmaceuticals Inc

https://www.evaluate.com/node/16950/pdf

Other oligomer-targeting projects are at the preclinical stage, and Acumen lists the likes of Alzinova, PromisNeurosciences, Kalgene Pharmaceuticals and Wren Therapeutics among its potential rivals. The last two groups are privately held – maybe a resurgence of interest in amyloid-beta could prompt them to follow Acumen onto the public markets.

G1945V

<< Previous

Bullboard Posts

Next >>

Report: New, more dangerous malware used in increasing cyberattacks